GSKs new strategy has a strong focus on growing an understanding of the role the immune system plays in human disease as well as leveraging the increasingly large amount of human genetic and gnomic information to identify novel targets
2“Science x Technology x culture = Next generation of medicines for patients” is GSKs new approach to R&D as introduced by the newly appointed Chief Scientific Officer and President of R&D, Hal Barron. Hal has joined GSK from the google backed biotech company Calico. The new strategy has a strong focus on growing an understanding of the role the immune system plays in human disease as well as leveraging the increasingly large amount of human genetic and gnomic information to identify novel targets and powerful medicines. As part of this GSK has teamed up with “23 and me” to leverage genetic insight for the development of these new novel medicines.
The talk will include an oversight of the following:
Bjørg Hunter, Device Engineering Manager, PSDE - Device Eng - UK, R&D Platform Technology & Science, GlaxoSmithKline holds a BSc in Design and Innovation Engineering from Technical University of Denmark and an MSc in Biomedical Engineering from Aarhus University, Denmark. Bjørg has been with GSK since graduating and has held different roles within the Device Engineering Group. In 2015 Bjørg moved into the late stage parenterals area as device lead for key GSK parenteral devices, working closely with internal GSK project teams and external partners. She progressed into leading a device management team in January 2017, where she has accountability of project management and regulatory compliance for parenteral devices. Bjørg has presented at several key pharmaceutical conferences on pharmaceutical topics, specifically in relation to combination product and regulatory guidance.
IDA har optaget mange webinarer med interessant viden inden for naturvidenskab og teknologi samt personlig udvikling. Se videoer med viden.